Integrated Preclinical Profiling

We can leverage many of our proprietary patient-derived xenograft (PDX) models and cell lines to perform integrated preclinical profiling of anticancer agents. Many of the models in our library correspond to established cell lines that have been derived from the xenograft model. Currently, we have more than 60 of these cell lines, which have been established with high conservation respective to their parent cell lines.

This unique capability enables you to use the same tumor entity throughout your 2D, 3D and in vivo assays. This approach to your program keeps efficiency and cost in mind, while letting you quickly collect the best study data. By using the same tumor model in your assays, we can leverage our extensive biomarker database, and offer insight and clinically relevant information throughout the life of your study.

You may also be interested in...

Purple cancer cell

Featured Story

As head of the Tumor Biology Modeling Lab, Julia Schüler, PhD, DVM, brings a breadth of experience and a plan to improve clinical success rates of our clients’ oncology discovery programs.

Webinar Replay

View our recent webinar on cost- and time-effective methods of determining the most appropriate in vivo models for your oncology preclinical program.

Syngeneic Models

Charles River offers syngeneic mouse models suitable for the evaluation of immunobiological-based therapies.

Logo screenshot

Charles River’s Entire Discovery Portfolio

Charles River offers the most comprehensive drug discovery service portfolio in the industry, supported by scientific excellence across major therapeutic areas and target classes.